AzTrials
AzTrials

Children and Youth With Medical ComplexityPITCareNCT06093386

Promoting Intensive Transitions for Children and Youth With Medical Complexity From Pediatric to Adult Care

A study testing Intensive Transition Support in people with Children and Youth With Medical Complexity, run by The Hospital for Sick Children at 1 site in Canada.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Medical advances have allowed many more children and youth with medical complexity (CMC) to survive well into adulthood. However, this has not been matched with increases in knowledge of complex conditions or the availability of supports as they transition into the adult care system. Read more about this study

Who is it for?
Ages 210 to 213 months
What is being tested?
Intensive Transition Support
Could I receive a placebo?
No, everyone receives an active treatment
How many people
144 participants
Where
1 siteCanada
Study dates
24 Nov 2023to 30 Apr 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 210 to 213 months
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Patients 17 years 6 months- 17 years 9 months old (inclusive) who meet Ontario's CMC definition:
  • technology dependence and/or users of high-intensity care,
  • fragility (severe and/or life-threatening condition,
  • chronicity (expected to last at least 6 months),
  • complexity (involvement of ≥5 healthcare practitioners/teams and healthcare services in ≥ 3 locations such as home, school, hospital, etc.).

Who cannot join

  • are expected to die within 2 years of recruitment (e.g., those receiving active end-of-life care)
  • do not have a stable primary caregiver (e.g., those who reside in residential or long-term care facilities, and those in foster care as the intervention is focused on a patient-caregiver dyad)

Trial locations and contacts

1 site in 1 country.

Canada1 site
  • The Hospital for Sick Children

    Toronto, Ontario

Other trials in Canada

About this study

Medical advances have allowed many more children and youth with medical complexity (CMC) to survive well into adulthood. However, this has not been matched with increases in knowledge of complex conditions or the availability of supports as they transition into the adult care system. The goal of this randomized control trial is to compare intensive transition support from a transition team, led by an advance practice nurse, during transition to adult care for 2 years, with usual care in CMC. Participants assigned to the intervention group will be offered support in care planning, receiving funding, and connecting with a primary care provider and adult subspecialists.

The main questions it aims to answer are:

  1. Does intensive transition support improve the patient's continuity of care over 2 years compared with usual care?
  2. Will there be differences between intervention and control groups with respect to other outcomes related to the youth/family's satisfaction with care, care coordination, self-care, health service utilization, cost-effectiveness, and quality of life?
  3. What are the experiences of youth, parents, the transition team, and other clinicians involved in the intensive transition support process?
Being tested
Intensive Transition Support
Keywords
transition, complex care

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Intensive Transition SupportOther

    Participants assigned to the intervention arm will transfer their transition support leadership to a transition team composed of a transition navigator (an advance practice nurse), a nurse navigator (a registered nurse) and a social worker over 2 years to support them through the multiple phases of CMC transitions including guidance, monitoring, planning, care transfer and transfer completion. CMC and their caregivers will be offered support in care planning, receiving funding, and connecting with a primary care provider and adult subspecialists.

Study groups in NCT06093386
Study groupRoleWhat they receive
InterventionExperimentalNot described
Receives: Other: Intensive Transition Support
Control/ Usual CareNo interventionStandard of care in the control group will involve the utilization of existing tools within clinical programs which may include preparation for transitions, but there will be no systematic follow-up by a paediatric provider beyond age 18. Care will be transferred to adult providers (primary care and specialists) via a transition guide that will be offered to participants and their referring providers. This is the current model of care for virtually all CMC in Ontario.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Transfer Completion

    Successful transfer of primary and subspecialty care to continuous primary care and a prioritized subspecialty in adult care will be measured using a relational continuity of care measure - the Bice Boxerman Index (modified for the study population).

    Measured: 6 to 30 months

Secondary outcomes (17)
  1. Transfer Completion

    Successful transfer of primary and subspecialty care to continuous primary care and a prioritized subspecialty in adult care will be measured using a relational continuity of care measure - the Bice Boxerman Index (modified for the study population).

    Measured: Baseline to 24 months

  2. Transfer Completion

    Successful transfer of primary care to continuous adult primary care will be measured using a relational continuity of care measure - the Bice Boxerman Index.

    Measured: 6 to 30 months

  3. Transfer Completion

    Successful transfer of subspecialty care to continuous care from a prioritized subspeciality provider in adult care will be measured using a relational continuity of care measure - the Bice Boxerman Index.

    Measured: 6 to 30 months

  4. Transfer Completion

    Successful transfer of subspecialty care to continuous care from all subspecialty providers in adult care will be measured using a relational continuity of care measure - the Bice Boxerman Index.

    Measured: Baseline to 24 months

  5. Transfer Completion

    The proportion of patients who receive a Bice Boxerman Index score of 0 (< 2 visits to both a subspecialty and primary care provider) will be assessed.

    Measured: Baseline to 24 months

  6. Transfer Completion

    The proportion of visits to all primary care providers that are made to the usual care provider will be assessed among individuals who had ≥ 3 primary care visits (UPC Index).

    Measured: Baseline to 24 months

  7. Early Identification and Transition Readiness- Satisfaction with Transitional Healthcare

    The change in caregiver satisfaction with transitional health care services will be measured using the Larsen Client Satisfaction Questionnaire (CSQ) (8-item). The change in patient satisfaction will also be measured with the CSQ where able. Comparisons will be made between intervention and control groups.

    Measured: Baseline, 12 months and 24 months

  8. Early Identification and Transition Readiness- Self-Care

    The change in the caregiver's family empowerment status will be measured with the Family Empowerment Scale (24-item). Scoring will be accomplished by summing responses from items within the family (12 items) and service system (12 items) to generate sub-scores. Comparisons will be made between intervention and control groups.

    Measured: Baseline, 12 months and 24 months

  9. Early Identification and Transition Readiness- Self-Care

    The change in the patient's knowledge and confidence in managing their health will be measured (if able) using the Patient Activation Measure (10-item). Comparisons will be made between intervention and control groups.

    Measured: Baseline

  10. Information Sharing and Support, Transition Plan and Coordinated Transition

    The change in utility of care planning tools, written transition plan assessment, coordination of care among providers and families and, coordination of care between providers and families will be assessed with the Family Experiences with Coordination of Care (FECC) survey, completed by the caregiver. Comparisons will be made between intervention and control groups.

    Measured: Baseline, 12 months and 24 months

  11. Introduction to Adult Services

    The number of patients who have received (presence or absence) adult-oriented funding and services will be assessed via report by the caregiver or, if able, the youth (e.g., receipt of Ontario Disability Support Program ODSP funding). Comparisons will be made between intervention and control groups.

    Measured: 24 months

  12. Use of Services

    Low acuity emergency department visits, emergency department use, hospitalization, technological complications, and immunization will be captured using encoded health administrative data housed at ICES to determine the patient's health care and preventative care use. Comparisons will be made between intervention and control groups.

    Measured: Baseline to 24 months

  13. Use of Services- Incremental Cost-Utility Ratio (ICUR)

    A probabilistic cost-utility analysis will be conducted using patient-level data, to determine the incremental cost per quality-adjusted life-year gained (QALY) of intensive transition support compared to usual care, from a health system perspective. QALY gains for both patient and caregiver will be included. All direct health care costs and health service utilization will be ascertained from study data linked to administrative datasets at ICES. Utility, determined by mapping patient and caregiver responses to the EQ-5D-5L, will be used to generate QALY gains (or losses) over the time horizon.

    Measured: Baseline to 24 months

  14. Health-Related Quality of Life

    The change in overall health-related quality of life of both the patient and their caregiver will be measured using the EQ-5D-5L. The digit for each of the scale's five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) can be combined into a 5-digit number that describes the patient's health state and is commonly used to estimate health utilities. The descriptive system is complemented by a visual analogue scale where patients record their self-rated health. Comparisons will be made between intervention and control groups.

    Measured: Baseline, 12 months and 24 months

  15. Health-Related Quality of Life-Caregiver Fatigue

    The change in caregiver fatigue will be measured using the PROMIS Fatigue Scale (8-item). The Fatigue scale is divided into the experience of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities. Each question has five response options ranging in value from one to five. Comparisons will be made between intervention and control groups.

    Measured: Baseline, 12 months and 24 months

  16. Health-Related Quality of Life- Family Distress

    The change in family distress will be assessed using the Brief Family Distress Scale (1-item) completed by the caregiver. The 10-point Likert scale is used to measure crisis level, which is assigned by groupings of the scale continuum, with a level between 1-3 indicating no impairment, 4-5, moderate impairment, and 6-10, marked impairment. Comparisons will be made between intervention and control groups.

    Measured: Baseline, 12 months and 24 months

  17. Experiences in The Process

    Semi-structured qualitative interviews will be conducted with a subset of intervention participants, health care providers, including both pre-transition and post-transition clinicians, and the transition team to gauge their experience with the transition support process.

    Measured: 12 to 24 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Oct 2023
  2. Study start24 Nov 2023
  3. Primary completion30 Apr 2026
  4. Study completion30 Apr 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Health services research
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
144 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06093386
Sponsor's protocol ID
1000080621
Acronym
PITCare
Status last verified
Aug 2026
First submitted
10 Oct 2023
Last updated
10 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Santos S, Thomson D, Diaz S, Soscia J, Adams S, Amin R, Bernstein S, Blais B, Bruno N, Colapinto K, Espin S, Fayed N, Greenaway J, Henze M, Ivers NM, LeGrow K, Lim A, Lippett R, Lunsky Y, Macarthur C, Mahant S, Malecki S, Miranda S, Moharir M, Moretti ME, Phillips L, Robeson P, Taryan M, Thorpe K, Toulany A, Vandepoele E, Weitzner B, Orkin J, Cohen E. Promoting Intensive Transitions for Children and Youth with Medical Complexity from Paediatric to Adult Care: the PITCare study-protocol for a randomised controlled trial. BMJ Open. 2024 Dec 9;14(12):e086088. doi: 10.1136/bmjopen-2024-086088.

    PubMed 39653557

Questions about this trial

What is this clinical trial studying?

A study testing Intensive Transition Support in people with Children and Youth With Medical Complexity, run by The Hospital for Sick Children at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 10 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Transfer Completion (time frame: 6 to 30 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06093386, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Aug 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in